Dendreon talks up a new drug
I just listened to Dendreon CEO Mitchell Gold's presentation this morning at the Bank of America Health Care Conference (Listen to it here), and he didn't say anything new on Provenge, the company's...
View ArticleDendreon presents data on its new drug
At the American Urological Association's annual meeting today, Dendreon presented pre-clinical data for the first time showing that its Trp-p8-related compound, known as D-3263, could be beneficial in...
View ArticleEchoes of Provenge in cancer chief’s comments
BusinessWeek has an interview this morning with Richard Pazdur, the director of the FDA's office of oncologic drugs.
View ArticleProvenge advocates rally in Seattle area
The controversy over prostate cancer treatment Provenge came to a head in the Seattle area Friday, as roughly 15 people rallied in front of Westlake Center and outside the FDA offices in Bothell,...
View ArticleNotes from Dendreon’s annual meeting
I didn't attend Dendreon's annual meeting today (I was in Everett at a media preview of Paul Allen's collection of vintage aircraft), but two analysts at McAdams Wright Ragen attended and they sent me...
View ArticleDendreon files to possibly raise $300 million
Dendreon filed a shelf registration this morning, saying that from time to time it might sell stock, warrants and debt at a value of up to $300 million.
View ArticleGilead Sciences drug awaits word from the FDA
Could three drugs developed in Seattle be approved by the Food and Drug Administration this year?
View ArticleDendreon initiates new Provenge study
In March, Dendreon executives said they would initiate two new clinical trials of the company's Provenge prostate cancer treatment this year -- one in 40 men with localized prostate cancer undergoing...
View ArticleDendreon expects Provenge results in October
Dendreon said this morning that it expects to receive the interim analysis of the results of a trial of its Provenge prostate cancer treatment this October.
View ArticleNCI officials had doubts about Provenge
Advocates pushing for the FDA to approve Dendreon's Provenge are sending around e-mails today showing that officials at the National Cancer Institute did not want the FDA to approve the drug.
View ArticleSEC closes Dendreon inquiry
The Securities and Exchange Commission has completed an inquiry into Dendreon Corp. and won't take any action, Dendreon said in a filing today.
View ArticleEarnings: Dendreon’s non-news call
Listening to Dendreon's earnings conference call yesterday afternoon, what stood out to me was the lack of any news.
View ArticleDendreon initiates another Provenge trial
Dendreon Corp. said it had started a new trial of its Provenge prostate cancer treatment in 120 men with advanced prostate cancer that does not respond to standard hormone therapy.
View ArticleStories to watch: Provenge
Fourth in a series on the blog looking at stories to watch during the coming months
View ArticleRound-up: Dendreon, SonoSite
A day after rival Cell Genesys halted a trial of its prostate cancer drug due to safety questions, Dendreon's stock actually inched up 1.4 percent. Some reports appeared to suggest that Cell Genesys'...
View Article
